Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma

Przybyszowski, Marek; Gross‐Sondej, Iwona; Zarychta, Jacek; Bazan-Socha, Stanisława; Bochenek, Grażyna; Soja, Jerzy; Sładek, Krzysztof

doi:10.1183/13993003.congress-2021.pa894

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improved airway remodeling (e.g., reduction in bronchial wall thickness) was better noticeable in invasive EBUS than in non-invasive HRCT. 143 In the phase 2 CASCADE study, tezepelumab increased the CT scan-determined lumen area across airway generations. 132 Hyperpolarized helium-3 MRI of the lung has demonstrated regional heterogeneity of lobar ventilation in asthma, 144 which is correlated with asthma severity.…”

Section: Imaging Of Airway Remodelingmentioning

confidence: 99%

“…A recent study evaluated the impact of one‐year mepolizumab therapy on airway remodeling through EBUS and HRCT. Improved airway remodeling (e.g., reduction in bronchial wall thickness) was better noticeable in invasive EBUS than in non‐invasive HRCT 143 . In the phase 2 CASCADE study, tezepelumab increased the CT scan‐determined lumen area across airway generations 132 …”

Section: Airway Remodelingmentioning

confidence: 99%

See 1 more Smart Citation

Biologics and airway remodeling in severe asthma

Varricchi

Ferri

Pepys

et al. 2022

Allergy

103

View full text Add to dashboard Cite

Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling. The introduction of biologics in severe asthma has led in some patients to the complete normalization of previously considered irreversible airflow obstruction. This highlights the need to distinguish a "fixed" airflow obstruction due to structural changes unresponsive to current therapies, from a "reversible" one as demonstrated by lung function normalization during biological therapies not previously obtained even with high-dose systemic glucocorticoids. The mechanisms by which exposure to environmental factors initiates the inflammatory responses that trigger airway remodeling are still incompletely understood. Alarmins represent epithelial-derived cytokines that initiate immunologic events leading to inflammatory airway remodeling. Biological therapies can improve airflow obstruction by addressing these airway inflammatory changes. In addition, biologics might prevent and possibly even revert "fixed" remodeling due to structural changes. Hence, it appears clinically important to separate the therapeutic effects (early and late) of biologics as a new paradigm to evaluate the effects of these drugs and future treatments on airway remodeling in severe asthma.

show abstract

Section: Imaging Of Airway Remodelingmentioning

confidence: 99%

Section: Airway Remodelingmentioning

confidence: 99%

Biologics and airway remodeling in severe asthma

Varricchi

Ferri

Pepys

et al. 2022

Allergy

103

View full text Add to dashboard Cite

show abstract

“…A recent study evaluated the impact of oneyear mepolizumab therapy on airway remodeling through EBUS and HRTC. Improved airway remodeling (e.g., reduction in bronchial wall thickness) was better noticeable in invasive EBUS than in non-invasive HRCT 202 . In the phase 2 CASCADE study, tezepelumab increased the CT scan-determined lumen area across airway generations 189 .…”

Section: Imaging Of Airway Remodelingmentioning

confidence: 91%

Biologics and Airway Remodeling in Severe Asthma

Varricchi

Ferri

Pepys

et al. 2022

Preprint

View full text Add to dashboard Cite

Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling. The introduction of biologics in severe asthma has led in some patients to the complete normalization of previously considered irreversible airflow obstruction. This highlights the need to distinguish a “fixed” bronchial obstruction due to structural changes unresponsive to current therapies, from a “reversible” one as demonstrated by lung function normalization during biological therapies not previously obtained even with high dose systemic glucocorticoids. The mechanisms by which exposure to environmental factors initiates the inflammatory responses that trigger airway remodeling are still incompletely understood. Alarmins represent tissue-derived cytokines that initiate immunologic events leading to inflammatory airway remodeling. Biological therapies can improve airflow obstruction by addressing these airway inflammatory changes. In addition, biologics might prevent and possibly even revert “fixed” remodeling due to structural changes. Hence, it appears clinically important to separate the therapeutic effects (early and late) of biologics as a new paradigm to evaluate the effects of these drugs and future treatments on airway remodeling in severe asthma.

show abstract

Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma

Cited by 2 publications

References 0 publications

Biologics and airway remodeling in severe asthma

Biologics and airway remodeling in severe asthma

Biologics and Airway Remodeling in Severe Asthma

Contact Info

Product

Resources

About